| Identification | Back Directory | [Name]
Pyranoridine phosphate | [CAS]
76748-86-2 | [Synonyms]
phosphate(1:4)
pyranoridinephosphate
Pyranaridine tetraphosphate
PYRANORIDINE TETRAPHOSPHATE
Pyranoridine phosphate ISO 9001：2015 REACH
4-((7-chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pheno
2-Methoxy-7-chloro-10[3′,5′-bis(pyrrolidinyl-1-methyl-)4′-hydroxyphenyl]aminobenzyl-(b)-1,5-naphthyridine tetraphosphate
4-[(7-Chloro-2-methoxy-1,5-dihydropyrido[3,2-b]quinolin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one phosphate (1:4)
4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one,phosphoricaci
4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one,phosphoric acid | [Molecular Formula]
C29H44ClN5O18P4 | [MDL Number]
MFCD05863545 | [MOL File]
76748-86-2.mol | [Molecular Weight]
910.03 |
| Chemical Properties | Back Directory | [Melting point ]
233-236° (dec) | [storage temp. ]
2-8°C | [solubility ]
acetic acid: soluble5mg/mL | [form ]
solid | [color ]
Light yellow to yellow | [InChIKey]
YKUQEKXHQFYULM-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Uses]
antimalarial | [Biological Activity]
pyronaridine (pnd), a synthetic quinolone derivative frequently prescribed for the treatment of malaria, is a selective and potent multidrug resistance (mdr) modulator of pgp-mediated mdr that inhibits the proliferation of a variety of tumor cells, including myeloid leukemia (k562 and k562/a02), epidermoid carcinoma (kb and kbv200), breast carcinoma (mcf-7 and mcf-7/adr), ovarian carcinoma (skov3, es-2 and pa-1), gastric carcinoma (bgc-823), colon carcinoma (lovo), hepatocellular carcinoma (smmz-7721 and qgy-7703), with the half maximal inhibition concentration ic50 values of 8.3 μm, 5.6 μm, 20.8 μm, 14.5 μm, 9.5 μm, 11 μm, 9.7 μm, 12.9 μm, 15.7 μm, 14.9 μm, 21.4 μm, 10.9 μm and 17.1 μm respectively [1]. | [in vivo]
Pyronaridine (57 mg/kg, oral administration, q.d. for 30 days) tetraphosphate reduces the parasitic burden in the Echinococcus granulosus-infected mice[2].
Pyronaridine (57 mg/kg, intraperitoneal injection, q.d. for 3 days) tetraphosphate reduces the parasitic burden in secondarily infected (cysts) mice[2].
Pyronaridine (57 mg/kg, intraperitoneal injection, for a single dose) tetraphosphate exhibits a higher exposure in the liver than in the plasma in male ICR mice[2].
| Animal Model: | Echinococcus granulosus-infected mice model[2] | | Dosage: | 57 mg/kg | | Administration: | Oral administration, q.d. for 30 days | | Result: | Reduced 42.4% of parasite wet weight and killed 90.7% of secondary infection (cysts) of E. granulosus ss. |
| [IC 50]
Plasmodium | [storage]
Store at RT | [References]
[1] qi j, wang s, liu g, peng h, wang j, zhu z, yang c. pyronaridine, a novel modulator of p-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. biochem biophys res commun. 2004 jul 9;319(4):1124-31. |
|
|